华森制药连发三项公告 高新技术企业认定、药品再注册事项落地

Group 1 - The core viewpoint of the news is that Huason Pharmaceutical (002907) has made significant announcements regarding its subsidiary's recognition as a high-tech enterprise, drug re-registration approvals, and shareholder equity changes, all of which indicate stable operations and control [1][2] Group 2 - Huason Pharmaceutical's wholly-owned subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., has been recognized as a national high-tech enterprise for the first time, with a certificate valid for three years, allowing it to pay corporate income tax at a reduced rate of 15%, which will lower operational costs and support R&D in the biopharmaceutical sector [1] - The company announced that eight of its drugs, including injectable moxifloxacin and sodium cytidine diphosphate, have passed re-registration, covering critical clinical needs in areas such as anti-infection and cardiovascular treatment, with the approval numbers valid until 2031, ensuring normal production and sales in the future [1] Group 3 - The equity change announcement revealed that the controlling shareholder, Chengdu Dajian, and its concerted parties plan to reduce their holdings by a total of 20.8799 million shares, accounting for 5% of the company's total share capital, decreasing their combined shareholding from 70% to 65%, while the controlling shareholder and actual controller remain unchanged, with no significant impact on operations [2] - The reduced holdings have generated approximately 353 million yuan in cash based on the weighted average stock price during the period, and some shareholders' remaining reduction plans will be executed at an opportune time [2]